title: Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.
authors.forename: V
authors.initials: V
authors.lastname: Kunzmann
authors.forename: T
authors.initials: T
authors.lastname: Ruediger
authors.forename: M
authors.initials: M
authors.lastname: Hallek
authors.forename: H K
authors.initials: HK
authors.lastname: Mueller-Hermelink
authors.forename: M
authors.initials: M
authors.lastname: Wilhelm
mesh_terms: D000368:Aged; D000371:Agglutination; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001808:Blood Vessels / Q000473:pathology; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D018921:Leukostasis / Q000209:etiology* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000473:pathology; D008297:Male; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016207:Cytokines; D000069283:Rituximab